Incyte | INCY - Ebit


Incyte reported $383.88M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agenus USD -13.31M 19.08M Mar/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
BioCryst Pharmaceuticals USD -4.51M 12.2M Dec/2024
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD -9.19B 13.87B Jun/2025
Novartis USD 4.48B 343M Sep/2025
Pfizer USD 4.65B 71M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025